Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model

Yamada, Keizo; Tsuji, Hajime; Kimura, Shinzo; Kato, Hisato; Yano, Shingo; Ukimura, Naoki; Yamada, Yuka; Nakagawa, Keigo; Nakagawa, Masao

doi:10.1016/s0049-3848(03)00105-1

Cited by 14 publications

(13 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, the use of DS extracted from marine resources could also contribute to the valorization of by‐products. However, even if promising in vitro results were reported by using heparan‐sulfates, some in vivo issues could be revealed since the heparin binding sites need to be accessible in order to observe an in vivo heparin bioactivity . To address these concerns, we have developed a PET‐DS patch for cardiovascular applications with in vitro and in vivo available DS active sites, which enhance its haemocompatibility.…”

Section: Discussionmentioning

confidence: 99%

In vitro and in vivo hemocompatibility evaluation of a new dermatan sulfate-modified PET patch for vascular repair surgery

Dhahri

Rodriguez-Ruiz

Aid‐Launais

et al. 2016

J. Biomed. Mater. Res.

View full text Add to dashboard Cite

The development of new vascular devices requires to study the effects of materials on blood cells and on coagulation, both in vitro and in vivo. In this study, we have developed a new material by grafting dermatan sulfate (DS) from shark skin onto polyethylene terephthalate (PET). We have evaluated the haemocompatibility of PET-DS material in vitro by measuring thrombin generation, plasma recalcification time, hemolytic activity, and platelet adhesion and in vivo with a model of vascular patch in rat abdominal aorta. In vitro, our results have shown that PET-DS is a nonhemolytic material, able to inhibit thrombin generation and platelet adhesion. In vivo studies by Doppler echographic evaluation 20 days after implantation have shown that the PET-DS patch was integrated in the vessel wall and covered by a layer of cells. In conclusion, PET-DS has good haemocompatibility properties and could be a promising tool for vascular surgery. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 105B: 2001-2009, 2017.

show abstract

Section: Discussionmentioning

confidence: 99%

In vitro and in vivo hemocompatibility evaluation of a new dermatan sulfate-modified PET patch for vascular repair surgery

Dhahri

Rodriguez-Ruiz

Aid‐Launais

et al. 2016

J. Biomed. Mater. Res.

View full text Add to dashboard Cite

show abstract

“…Treatment involves discontinuation of heparin, removal of thrombus if viability of the patient or a limb is compromised, and use of direct thrombin inhibitors (7). Alternative anti-thrombotic agents including lepirudin, argatroban, and danaparoid have been used to speed up thrombolysis while preventing new thrombosis (7)(8)(9)(10). Safety and efficacy of argatroban is documented, as there is no increased risk of major bleeding (8).…”

Section: Discussionmentioning

confidence: 99%

“…Safety and efficacy of argatroban is documented, as there is no increased risk of major bleeding (8). Other agents such as prostacyclin analogue iloprost, platelet inhibitors such as clopidogrel, II-b,III-a inhibitors such as abciximab and tirofiban, and X-a inhibitors, for example, ximelagatran, also are being investigated (9,10).…”

Section: Discussionmentioning

confidence: 99%

Hard-Hearted “HITT” to the Heart (Mural Thrombus from Heparin-Induced Thrombocytopenia with Thrombosis Syndrome)

Geninatti

Frouge

2009

The Journal of Emergency Medicine

View full text Add to dashboard Cite

“…The simultaneous use of alteplase and argatroban is documented minimally in the literature [5][6][7][8][9][10][11]. To our knowledge, there is only one case report describing the use of concomitant alteplase and argatroban for the treatment of acute thrombosis in lower extremities.…”

Section: Commentarymentioning

confidence: 99%

Argatroban and catheter‐directed thrombolysis with alteplase for limb‐ and graft‐threatening thromboses in a patient with a history of HIT

Maldonado

2009

American J Hematol

View full text Add to dashboard Cite

A 73-year-old, 6 0 0@, 130 kg, white male who is selfemployed as a farmer presented to the hospital with a chief complaint of severe nausea, vomiting, and diarrhea accompanied by dizziness and diaphoresis occurring since that morning. His family and social history were noncontributory. On examination, the patient appeared comfortable and in no acute distress. The blood pressure was 92/56 mmHg, the pulse 68 beats per minute, the temperature 97.68F, the respiratory rate 18 breaths per minute, and the oxygen saturation 95% on room air. Lung sounds were diminished bilaterally in the bases. The remainder of a 10-point review of systems was negative except for an elevated serum creatinine (1.6, 1.2 mg/dL baseline), BUN (30 mg/dL), and white blood cell count (14.4 K/lL).The patient's initial presentation was consistent with a bacterial or viral gastroenteritis along with acute renal failure secondary to volume depletion. Other factors that predisposed him to gastrointestinal symptoms included longterm immunosuppression with mycophenolate mofetil as well as uremia.The patient has an extensive medical history that includes relevant disease states. The patient is 5 years post living donor kidney transplant secondary to chronic renal failure from ischemic nephropathy. His course immediately following transplant was complicated by deep venous thromboses in the right femoral and popliteal veins and pulmonary embolism secondary to hypercoagulability disorders including documented elevated anticardiolipin IgM antibody and protein S deficiency in the setting of a normal protein C level. Heparin and warfarin therapy had been initiated at the time of diagnosis. He developed thrombocytopenia and a heparin-induced thrombocytopenia (HIT) antibody test was reported in the record as weakly positive. He was subsequently treated with fondaparinux and warfarin but developed a diverticular bleed within 1 month. Anticoagulation was discontinued and an inferior vena cava filter was placed. The patient then opted against chronic anticoagulation. His current medications at the time of admission include alendronate, allopurinol, aspirin, calcium carbonate, carvedilol, ferrous sulfate, fish oil, furosemide, glipizide, multivitamins, mycophenolate mofetil, pantoprazole, prednisone, tacrolimus, and tamsulosin. His listed allergies include an unknown reaction to atenolol, itching with cephalexin, and heparin-induced thrombocytopenia.Upon admission, blood, stool, and urine cultures were obtained and subsequently were negative. FK506 and MMF levels were within normal limits making it unlikely that drug toxicity was causing his symptoms. An unenhanced abdominal CT demonstrated acute diverticulitis and the patient was started on ciprofloxacin and metronidazole for treatment.On the 2nd day of admission, the patient's serum creatinine continued to rise and he became oliguric. He also developed bilateral lower extremity edema, pain, cyanosis, and mottling. Due to his worsening renal function, the patient developed metabolic acidosis and because of this, ...

show abstract

Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model

Cited by 14 publications

References 39 publications

In vitro and in vivo hemocompatibility evaluation of a new dermatan sulfate-modified PET patch for vascular repair surgery

In vitro and in vivo hemocompatibility evaluation of a new dermatan sulfate-modified PET patch for vascular repair surgery

Hard-Hearted “HITT” to the Heart (Mural Thrombus from Heparin-Induced Thrombocytopenia with Thrombosis Syndrome)

Argatroban and catheter‐directed thrombolysis with alteplase for limb‐ and graft‐threatening thromboses in a patient with a history of HIT

Contact Info

Product

Resources

About